Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke

Molecular Diagnosis

Volumn 9, Issue 1, 2005, Pages 1-7

  Lescuyer, Pierre ^a,b   Allard, Laure ^a   Hochstrasser, Denis F ^a   Sanchez, Jean Charles ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Department of Structural Biology and Bioinformatics   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; FATTY ACID BINDING PROTEIN; BIOLOGICAL MARKER; CARRIER PROTEIN;

BIOLOGY; BRAIN; BRAIN INJURY; CONCENTRATION (PARAMETERS); DEGENERATIVE DISEASE; DISEASE MARKER; EARLY DIAGNOSIS; FATTY ACID TRANSPORT; HEART; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MOLECULAR BIOLOGY; PLASMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; STROKE; ACUTE DISEASE; CEREBROVASCULAR ACCIDENT;

ACUTE DISEASE; BIOLOGICAL MARKERS; BRAIN INJURIES; CARRIER PROTEINS; CEREBROVASCULAR ACCIDENT; EARLY DIAGNOSIS; FATTY ACID-BINDING PROTEINS; HUMANS; MYOCARDIAL INFARCTION; NEURODEGENERATIVE DISEASES;

EID: 26944463910     PISSN: 10848592     EISSN: 10848592     Source Type: Journal    
DOI: 10.2165/00066982-200509010-00001     Document Type: Review

References (69)

1. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002 Nov; 1 (11): 845-67
2. Adams III JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s? Circulation 1993 Aug; 88 (2): 750-63
3. Lewandrowski K, Chen A, Januzzi J. Cardiac markers for myocardial infarction: a brief review. Am J Clin Pathol 2002 Dec; 118 Suppl.: S93-9
4. Guillaume E, Zimmermann C, Burkhard PR, et al. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003 Aug; 3 (8): 1495-9
5. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, et al. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004 Jan; 3 (1): 66-72
6. Schaap FG, Binas B, Danneberg H, et al. Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 1999; 85: 329-37
7. Wolfrum C, Borrmann CM, Borchers T, et al. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001; 98: 2323-8
8. Glatz JF, Storch J. Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol 2001; 12: 267-74
9. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996; 35: 243-82
10. Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000; 1486: 28-44
11. Paulussen RJ, van Moerkerk HT, Veerkamp JH. Immunochemical quantitation of fatty acid-binding proteins: tissue distribution of liver and heart FABP types in human and porcine tissues. Int J Biochem 1990; 22: 393-8
12. Zschiesche W, Kleine AH, Spitzer E, et al. Histochemical localization of heart-type fatty acid-binding protein in human and murine tissues. Histochem Cell Biol 1995; 103: 147-56
13. Van Nieuwenhoven FA, Kleine AH, Wodzig WH, et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation 1995; 92: 2848-54
14. Yoshimoto K, Tanaka T, Somiya K, et al. Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction. Heart Vessels 1995; 10: 304-9
15. Sellner PA, Chu W, Glatz JF, et al. Developmental role of fatty acid-binding proteins in the mouse brain. Dev Brain Res 1995; 89: 33-46
16. Myers-Payne SC, Hubbell T, Pu L, et al. Isolation and characterization of two fatty acid-binding proteins from mouse brain. J Neurochem 1996; 66: 1648-56
17. Pelsers M, Hanhoff T, van der Voort D, et al. Tissue specific types of fatty acid-binding proteins, B- and H-FABP, as novel markers for detection of brain injury. Clin Chem 2004; 50: 1568-75
18. Maatman RG, van de Westerlo EM, van Kuppevelt TH, et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney: use of the reverse transcriptase polymerase chain reaction. Biochem J 1992; 288: 285-90
19. Pelsers MM, Chapelle JP, Knapen M, et al. Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. Clin Chem 1999 Mar; 45 (3): 441-3
20. Katrukha A, Bereznikova A, Filatov V, et al. Improved detection of minor ischemic cardiac injury in patients with unstable angina by measurement of cTnI and fatty acid-binding protein (FABP) [abstract]. Clin Chem 1999; 45: A139
21. Pagani F, Bonora R, Bonetti G, et al. Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein. Ann Clin Biochem 2002 Jul; 39 (Pt 4): 404-5
22. Glatz JF, van Bilsen M, Paulussen RJ, et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 1988 Jul 1; 961 (1): 148-52
23. Knowlton AA, Apstein CS, Saouf R, et al. Leakage of heart fatty acid binding protein with ischemia and reperfusion in the rat. J Mol Cell Cardiol 1989 Jun; 21 (6): 577-83
24. Glatz JF, van der Vusse GJ, Simoons ML, et al. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 1998 Apr 6; 272 (1): 87-92
25. Wodzig KW, Kragten JA, Modrzejewski W, et al. Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins. Clin Chim Acta 1998 Apr 27; 272 (2): 209-23
26. Tanaka T, Hirota Y, Sohmiya K, et al. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991 Apr; 24 (2): 195-201
27. Kleine AH, Glatz JF, Van Nieuwenhoven FA, et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992 Oct 21; 116 (1-2): 155-62
28. Tsuji R, Tanaka T, Sohmiya K, et al. Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol 1993 Oct 1; 41 (3): 209-17
29. Ishii J, Wang JH, Naruse H, et al. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 1997 Aug; 43 (8 Pt 1): 1372-8
30. Okamoto F, Sohmiya K, Ohkaru Y. Human heart-type cytoplasmic fatty acid binding protein (H-FABP) for the diagnosis of acute myocardial infarction: clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 2000 Mar; 38 (3): 231-8
31. Haastrup B, Gill S, Kristensen SR, et al. Biochemical markers of ischaemia for the early identification of acute myocardial infarction without St segment elevation. Cardiology 2000; 94 (4): 254-61
32. Seino Y, Ogata K, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 2003 Aug 15; 115 (3): 185-90
33. Nakata T, Hashimoto A, Hase M, et al. Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 2003; 99 (2): 96-104
34. Seino Y, Tomita Y, Takano T, et al. Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J 2004 Feb; 68 (2): 144-8
35. Chan CP, Sanderson JE, Glatz JF, et al. A superior early myocardial infarction marker: human heart-type fatty acid-binding protein. Z Kardiol 2004 May; 93 (5): 388-97
36. Wu AHB, Feng YJ, Contois JH, et al. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci 1996; 26: 291-300
37. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004 Jul; 25 (14): 1187-96
38. Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. Rev Cardiovasc Med 2003 Fall; 4 (4): 216-27
39. Menon V, Harrington RA, Hochman JS. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 549S-75S
40. Jaffe A. Caveat emptor. Am J Med 2003 Aug 15; 115 (3): 241-4
41. Alansari SE, Croal BL. Diagnostic value of heart fatty acid binding protein and myoglobin in patients admitted with chest pain. Ann Clin Biochem 2004 Sep; 41 (Pt 5): 391-6
42. Ghani F, Wu AH, Graff L, et al. Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 2000 May; 46 (5): 718-9
43. Gorski J, Hermens WT, Borawski J, et al. Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. Clin Chem 1997 Jan; 43 (1): 193-5
44. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004 Jul 21; 44 (2): 276-86
45. Kucia AM, Zeitz CJ. Failed reperfusion after thrombolytic therapy: recognition and management. Heart Lung 2002 Mar-Apr; 31 (2): 113-21
46. Ishii J, Nagamura Y, Nomura M, et al. Early detection of successful coronary reperfusion based on serum concentration of human heart-type cytoplasmic fatty acid-binding protein. Clin Chim Acta 1997 Jun 27; 262 (1-2): 13-27
47. de Lemos JA, Antman EM, Morrow DA, et al. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. Clin Chim Acta 2000 Aug; 298 (1-2): 85-97
48. de Groot MJ, Muijtjens AM, Simoons ML, et al. Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma. Heart 2001 Mar; 85 (3): 278-85
49. Quinones MA. Risk stratification after myocardial infarction: clinical science versus practice behavior. Circulation 1997 Mar 18; 95 (6): 1352-4
50. Gibbons RJ, Valeti US, Araoz PA, et al. The quantification of infarct size. J Am Coll Cardiol 2004 Oct 19; 44 (8): 1533-42
51. Glatz JF, Kleine AH, van Nieuwenhoven FA, et al. Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 1994 Feb; 71 (2): 135-40
52. Wodzig KW, Kragten JA, Hermens WT, et al. Estimation of myocardial infarct size from plasma myoglobin or fatty acid-binding protein. Influence of renal function. Eur J Clin Chem Clin Biochem 1997 Mar; 35 (3): 191-8
53. de Groot MJ, Wodzig KW, Simoons ML, et al. Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates. Cardiovasc Res 1999 Nov; 44 (2): 315-24
54. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004 Apr; 97 (4): 187-98
55. Pelsers MM, Hermens WT, Glatz JFC. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005 Feb; 352 (1-2): 15-35
56. Noppe M, Crols R, Andries D, et al. Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology. Clin Chim Acta 1986 Mar 16; 155 (2): 143-50
57. Aurell A, Rosengren LE, Karlsson B, et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991 Oct; 22 (10): 1254-8
58. Nakagawa H, Yamada M, Kanayama T, et al. Myelin basic protein in the cerebrospinal fluid of patients with brain tumors. Neurosurgery 1994 May; 34 (5): 825-33
59. Lamers KJ, van Engelen BG, Gabreels FJ, et al. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995 Sep; 92 (3): 247-51
60. Ross SA, Cunningham RT, Johnston CF, et al. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 1996 Oct; 10 (5): 471-6
61. Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996 Sep 26; 335 (13): 924-30
62. Romner B, Ingebrigtsen T, Kongstad P, et al. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 2000 Aug; 17 (8): 641-7
63. de Vries J, Thijssen WA, Snels SE, et al. Intraoperative values of S-100 protein, myelin basic protein, lactate, and albumin in the CSF and serum of neurosurgical patients. J Neurol Neurosurg Psychiatry 2001 Nov; 71 (5): 671-4
64. Lamers KJ, Vos P, Verbeek MM, et al. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 2003 Aug 15; 61 (3): 261-4
65. Schellinger PD, Warach S. Therapeutic time window of thrombolytic therapy following stroke. Curr Atheroscler Rep 2004 Jul; 6 (4): 288-94
66. Schellinger PD, Kaste M, Hacke W. An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 2004 Feb; 17 (1): 69-77
67. Wunderlich MT, Hanhoff T, Goertler M, et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute iscaemic stroke. J Neurol 2005; 252 (6): 718-24
68. Steinacker P, Mollenhauer B, Bibl M, et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004 Nov 3; 370 (1): 36-9
69. Reynolds MA, Kirchick HJ, Dahlen JR, et al. Early biomarkers of stroke. Clin Chem 2003 Oct; 49 (10): 1733-9